Texas Medical Center

About: Texas Medical Center is a healthcare organization based out in Houston, Texas, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 2845 authors who have published 2394 publications receiving 79426 citations.

Medical dissolution of canine struvite uroliths

Abstract: Medical therapy is an effective method of canine struvite urolith dissolution. Recommendations include (1) eradication or control of urinary tract infection (if present), (2) use of calculolytic diets, and (3) administration of urease inhibitors to patients with persistent urinary tract infection caused by urease-producing microbes.

Animal model: Ceroidosis (ceroid‐lipofuscinosis) in Australian Cattle dogs

Abstract: Ceroid-lipofuscinosis is described in Australian Cattle dogs. Lesions included storage of ceroid-lipofuscin in most tissues with characteristic ultrastructural inclusion body patterns in neurons and other cells. Dolichol concentration of the affected dog's brain was similar to those in age-matched control dog brains. However, concentrations in brain, liver and kidneys were markedly higher than in a slightly younger dog. Biochemical data including lysosomal enzyme activities exclude other lysosomal storage diseases. The clinical and pathological features of this disorder resemble those of the juvenile Spielmeyer-Vogt type of Batten disease in humans.

Adult seafood allergy in the Texas Medical Center: A 13-year experience.

Abstract: There is a paucity of data regarding prevalence and characteristics of adult seafood allergy in United States cohorts. This study was designed to determine the characteristics of patient-reported s...

Outcomes and readmissions after transcatheter and surgical aortic valve replacement in patients with cirrhosis: A propensity matched analysis.

Abstract: Background The data on the comparative outcomes and readmissions after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with cirrhosis are limited. We compared mortality, complications, discharge disposition, 30-day readmission rates, length of stay, and cost of hospitalization in cirrhotic patients undergoing TAVR and SAVR. Methods The National Inpatient Sample (NIS) and the National Readmission Database (NRD) were used for the study. The International Classification of Diseases-9th version was used to define cohorts of patients undergoing TAVR and SAVR. Patients undergoing concomitant other valve or coronary bypass surgery were excluded. Propensity-score matching was used to compare the outcomes between the groups. Results From 2012 to 2014, a total of 126 and 157 patients with cirrhosis underwent TAVR and SAVR, respectively. Of the 283 patients, 16 (5.7%) died during the same hospitalization. We found 345 patients with cirrhosis who had undergone an aortic valve replacement (156 with TAVR, and 189 with SAVR) in the 2013 and 2014 NRD. On propensity matching, there were no significant differences between the in-hospital mortality, readmissions, hospitalization costs, and discharges to home within the TAVR and SAVR groups. However, post-procedure length of stay (6.3 vs. 10.2 days; P < 0.001) and blood transfusion rates (22% vs. 58%; P < 0.001) were significantly lower in TAVR patients. Conclusions Cirrhotic patients undergoing TAVR has high, but similar mortality and 30-day readmission rates when compared to SAVR; however, has shorter length of stay and lower blood transfusion rates.

Prediction of normal fetal growth by the Rossavik growth model using two scans before 27 weeks, menstrual age

Abstract: Individual growth curve standards for five fetal anatomic parameters (head and abdominal circumferences, head and abdominal cubes, and femur diaphysis length) and estimated fetal weight were prospectively developed in 70 pregnant women who delivered infants with growth considered appropriate-for-menstrual age. For this purpose, we used the Rossavik growth model (P = c (t)k + s(t)rpar;, model specification functions previously reported, and the data of two scans before 27.0 weeks of menstrual age, separated by an interval of at least 5 weeks. The anatomic parameters and estimated weights of these fetuses in the last 14 weeks of gestation were found to have values close to their projected standards. Whereas there was a significant, although small, systematic error of overprediction for most of the parameters and estimated fetal weight, deviations between observed and expected values were, with few exceptions, within the ranges established by Deter for normal growth. This study demonstrates that the Rossavik growth model could be used to predict normal fetal growth in a sample of patients different from those from which the model was developed.